Additional data are needed to establish whether incidence of HER2+ tumours, which are ER−, remains low since their treatment involves monoclonal antibodies, such as trastuzumab and pertuzumab,13,50 which are amongst the more expensive breast cancer treatments used by the NHS. Here, ERBB2 is linked to neoplasm.